Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
12.18
-0.32 (-2.56%)
May 29, 2026, 11:57 AM EDT - Market open
Corvus Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Corvus Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $33.33. The average 1-year stock price forecast is 173.65% higher than the current stock price, while the lowest is $27 (+121.67%) and the highest is $42 (+244.83%).
Price Target: $33.33 (+173.65%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Corvus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Buy Reiterates $30 | Buy | Reiterates | $30 | +146.31% | May 18, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $33 | Buy | Reiterates | $33 | +170.94% | May 15, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $40 | Buy | Maintains | $40 | +228.41% | May 15, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $27 | Buy | Reiterates | $27 | +121.67% | May 15, 2026 |
| Barclays | Barclays | Buy Maintains $28 | Buy | Maintains | $28 | +129.89% | May 15, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
8.61M
EPS This Year
-0.68
from -0.53
EPS Next Year
-0.85
from -0.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 15.1M | ||||||
| Avg | n/a | 8.6M | ||||||
| Low | n/a | 2.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.54 | -0.59 | ||||||
| Avg | -0.68 | -0.85 | ||||||
| Low | -0.81 | -1.10 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.